Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
5,078
archived clinical trials in
Major Depression Disorder (MDD)

A Study of Adjunctive Treatment to Antidepressant Therapy for Adults With Major Depressive Disorder
A Study of Augmentation With LY2216684 for Patients With Major Depressive Disorder Who Are Partial Responders to Selective Serotonin Reuptake Inhibitor Treatment
Status: Enrolling
Updated:  3/25/2018
Clinical Research Facility
mi
from
Austin, TX
A Study of Adjunctive Treatment to Antidepressant Therapy for Adults With Major Depressive Disorder
A Study of Augmentation With LY2216684 for Patients With Major Depressive Disorder Who Are Partial Responders to Selective Serotonin Reuptake Inhibitor Treatment
Status: Enrolling
Updated: 3/25/2018
Clinical Research Facility
mi
from
Austin, TX
Click here to add this to my saved trials
A Study of Adjunctive Treatment to Antidepressant Therapy for Adults With Major Depressive Disorder
A Study of Augmentation With LY2216684 for Patients With Major Depressive Disorder Who Are Partial Responders to Selective Serotonin Reuptake Inhibitor Treatment
Status: Enrolling
Updated:  3/25/2018
Clinical Research Facility
mi
from
Dallas, TX
A Study of Adjunctive Treatment to Antidepressant Therapy for Adults With Major Depressive Disorder
A Study of Augmentation With LY2216684 for Patients With Major Depressive Disorder Who Are Partial Responders to Selective Serotonin Reuptake Inhibitor Treatment
Status: Enrolling
Updated: 3/25/2018
Clinical Research Facility
mi
from
Dallas, TX
Click here to add this to my saved trials
A Study of Adjunctive Treatment to Antidepressant Therapy for Adults With Major Depressive Disorder
A Study of Augmentation With LY2216684 for Patients With Major Depressive Disorder Who Are Partial Responders to Selective Serotonin Reuptake Inhibitor Treatment
Status: Enrolling
Updated:  3/25/2018
Clinical Research Facility
mi
from
San Antonio, TX
A Study of Adjunctive Treatment to Antidepressant Therapy for Adults With Major Depressive Disorder
A Study of Augmentation With LY2216684 for Patients With Major Depressive Disorder Who Are Partial Responders to Selective Serotonin Reuptake Inhibitor Treatment
Status: Enrolling
Updated: 3/25/2018
Clinical Research Facility
mi
from
San Antonio, TX
Click here to add this to my saved trials
A Study in Participants With Major Depressive Disorder Who Are Partial Responders to Selective Serotonin Reuptake Inhibitor
A Randomized Placebo-Controlled, Double-Blind Study of LY2216684 Flexible-Dose 12 to 18 mg Once Daily as Adjunctive Treatment for Patients With Major Depressive Disorder Who Are Partial Responders to Selective Serotonin Reuptake Inhibitor Treatment
Status: Enrolling
Updated:  3/26/2018
Clinical Research Facility
mi
from
Brooklyn, NY
A Study in Participants With Major Depressive Disorder Who Are Partial Responders to Selective Serotonin Reuptake Inhibitor
A Randomized Placebo-Controlled, Double-Blind Study of LY2216684 Flexible-Dose 12 to 18 mg Once Daily as Adjunctive Treatment for Patients With Major Depressive Disorder Who Are Partial Responders to Selective Serotonin Reuptake Inhibitor Treatment
Status: Enrolling
Updated: 3/26/2018
Clinical Research Facility
mi
from
Brooklyn, NY
Click here to add this to my saved trials
A Study in Participants With Major Depressive Disorder Who Are Partial Responders to Selective Serotonin Reuptake Inhibitor
A Randomized Placebo-Controlled, Double-Blind Study of LY2216684 Flexible-Dose 12 to 18 mg Once Daily as Adjunctive Treatment for Patients With Major Depressive Disorder Who Are Partial Responders to Selective Serotonin Reuptake Inhibitor Treatment
Status: Enrolling
Updated:  3/26/2018
Clinical Research Facility
mi
from
Garden Grove, CA
A Study in Participants With Major Depressive Disorder Who Are Partial Responders to Selective Serotonin Reuptake Inhibitor
A Randomized Placebo-Controlled, Double-Blind Study of LY2216684 Flexible-Dose 12 to 18 mg Once Daily as Adjunctive Treatment for Patients With Major Depressive Disorder Who Are Partial Responders to Selective Serotonin Reuptake Inhibitor Treatment
Status: Enrolling
Updated: 3/26/2018
Clinical Research Facility
mi
from
Garden Grove, CA
Click here to add this to my saved trials
A Study in Participants With Major Depressive Disorder Who Are Partial Responders to Selective Serotonin Reuptake Inhibitor
A Randomized Placebo-Controlled, Double-Blind Study of LY2216684 Flexible-Dose 12 to 18 mg Once Daily as Adjunctive Treatment for Patients With Major Depressive Disorder Who Are Partial Responders to Selective Serotonin Reuptake Inhibitor Treatment
Status: Enrolling
Updated:  3/26/2018
Clinical Research Facility
mi
from
Oakland, CA
A Study in Participants With Major Depressive Disorder Who Are Partial Responders to Selective Serotonin Reuptake Inhibitor
A Randomized Placebo-Controlled, Double-Blind Study of LY2216684 Flexible-Dose 12 to 18 mg Once Daily as Adjunctive Treatment for Patients With Major Depressive Disorder Who Are Partial Responders to Selective Serotonin Reuptake Inhibitor Treatment
Status: Enrolling
Updated: 3/26/2018
Clinical Research Facility
mi
from
Oakland, CA
Click here to add this to my saved trials
A Study in Participants With Major Depressive Disorder Who Are Partial Responders to Selective Serotonin Reuptake Inhibitor
A Randomized Placebo-Controlled, Double-Blind Study of LY2216684 Flexible-Dose 12 to 18 mg Once Daily as Adjunctive Treatment for Patients With Major Depressive Disorder Who Are Partial Responders to Selective Serotonin Reuptake Inhibitor Treatment
Status: Enrolling
Updated:  3/26/2018
Clinical Research Facility
mi
from
Temecula, CA
A Study in Participants With Major Depressive Disorder Who Are Partial Responders to Selective Serotonin Reuptake Inhibitor
A Randomized Placebo-Controlled, Double-Blind Study of LY2216684 Flexible-Dose 12 to 18 mg Once Daily as Adjunctive Treatment for Patients With Major Depressive Disorder Who Are Partial Responders to Selective Serotonin Reuptake Inhibitor Treatment
Status: Enrolling
Updated: 3/26/2018
Clinical Research Facility
mi
from
Temecula, CA
Click here to add this to my saved trials
A Study in Participants With Major Depressive Disorder Who Are Partial Responders to Selective Serotonin Reuptake Inhibitor
A Randomized Placebo-Controlled, Double-Blind Study of LY2216684 Flexible-Dose 12 to 18 mg Once Daily as Adjunctive Treatment for Patients With Major Depressive Disorder Who Are Partial Responders to Selective Serotonin Reuptake Inhibitor Treatment
Status: Enrolling
Updated:  3/26/2018
Clinical Research Facility
mi
from
Waterbury, CT
A Study in Participants With Major Depressive Disorder Who Are Partial Responders to Selective Serotonin Reuptake Inhibitor
A Randomized Placebo-Controlled, Double-Blind Study of LY2216684 Flexible-Dose 12 to 18 mg Once Daily as Adjunctive Treatment for Patients With Major Depressive Disorder Who Are Partial Responders to Selective Serotonin Reuptake Inhibitor Treatment
Status: Enrolling
Updated: 3/26/2018
Clinical Research Facility
mi
from
Waterbury, CT
Click here to add this to my saved trials
A Study in Participants With Major Depressive Disorder Who Are Partial Responders to Selective Serotonin Reuptake Inhibitor
A Randomized Placebo-Controlled, Double-Blind Study of LY2216684 Flexible-Dose 12 to 18 mg Once Daily as Adjunctive Treatment for Patients With Major Depressive Disorder Who Are Partial Responders to Selective Serotonin Reuptake Inhibitor Treatment
Status: Enrolling
Updated:  3/26/2018
Clinical Research Facility
mi
from
Boca Raton, FL
A Study in Participants With Major Depressive Disorder Who Are Partial Responders to Selective Serotonin Reuptake Inhibitor
A Randomized Placebo-Controlled, Double-Blind Study of LY2216684 Flexible-Dose 12 to 18 mg Once Daily as Adjunctive Treatment for Patients With Major Depressive Disorder Who Are Partial Responders to Selective Serotonin Reuptake Inhibitor Treatment
Status: Enrolling
Updated: 3/26/2018
Clinical Research Facility
mi
from
Boca Raton, FL
Click here to add this to my saved trials
A Study in Participants With Major Depressive Disorder Who Are Partial Responders to Selective Serotonin Reuptake Inhibitor
A Randomized Placebo-Controlled, Double-Blind Study of LY2216684 Flexible-Dose 12 to 18 mg Once Daily as Adjunctive Treatment for Patients With Major Depressive Disorder Who Are Partial Responders to Selective Serotonin Reuptake Inhibitor Treatment
Status: Enrolling
Updated:  3/26/2018
Clinical Research Facility
mi
from
Fort Myers, FL
A Study in Participants With Major Depressive Disorder Who Are Partial Responders to Selective Serotonin Reuptake Inhibitor
A Randomized Placebo-Controlled, Double-Blind Study of LY2216684 Flexible-Dose 12 to 18 mg Once Daily as Adjunctive Treatment for Patients With Major Depressive Disorder Who Are Partial Responders to Selective Serotonin Reuptake Inhibitor Treatment
Status: Enrolling
Updated: 3/26/2018
Clinical Research Facility
mi
from
Fort Myers, FL
Click here to add this to my saved trials
A Study in Participants With Major Depressive Disorder Who Are Partial Responders to Selective Serotonin Reuptake Inhibitor
A Randomized Placebo-Controlled, Double-Blind Study of LY2216684 Flexible-Dose 12 to 18 mg Once Daily as Adjunctive Treatment for Patients With Major Depressive Disorder Who Are Partial Responders to Selective Serotonin Reuptake Inhibitor Treatment
Status: Enrolling
Updated:  3/26/2018
Clinical Research Facility
mi
from
North Bay Village, FL
A Study in Participants With Major Depressive Disorder Who Are Partial Responders to Selective Serotonin Reuptake Inhibitor
A Randomized Placebo-Controlled, Double-Blind Study of LY2216684 Flexible-Dose 12 to 18 mg Once Daily as Adjunctive Treatment for Patients With Major Depressive Disorder Who Are Partial Responders to Selective Serotonin Reuptake Inhibitor Treatment
Status: Enrolling
Updated: 3/26/2018
Clinical Research Facility
mi
from
North Bay Village, FL
Click here to add this to my saved trials
A Study in Participants With Major Depressive Disorder Who Are Partial Responders to Selective Serotonin Reuptake Inhibitor
A Randomized Placebo-Controlled, Double-Blind Study of LY2216684 Flexible-Dose 12 to 18 mg Once Daily as Adjunctive Treatment for Patients With Major Depressive Disorder Who Are Partial Responders to Selective Serotonin Reuptake Inhibitor Treatment
Status: Enrolling
Updated:  3/26/2018
Clinical Research Facility
mi
from
Oakland Park, FL
A Study in Participants With Major Depressive Disorder Who Are Partial Responders to Selective Serotonin Reuptake Inhibitor
A Randomized Placebo-Controlled, Double-Blind Study of LY2216684 Flexible-Dose 12 to 18 mg Once Daily as Adjunctive Treatment for Patients With Major Depressive Disorder Who Are Partial Responders to Selective Serotonin Reuptake Inhibitor Treatment
Status: Enrolling
Updated: 3/26/2018
Clinical Research Facility
mi
from
Oakland Park, FL
Click here to add this to my saved trials
A Study in Participants With Major Depressive Disorder Who Are Partial Responders to Selective Serotonin Reuptake Inhibitor
A Randomized Placebo-Controlled, Double-Blind Study of LY2216684 Flexible-Dose 12 to 18 mg Once Daily as Adjunctive Treatment for Patients With Major Depressive Disorder Who Are Partial Responders to Selective Serotonin Reuptake Inhibitor Treatment
Status: Enrolling
Updated:  3/26/2018
Clinical Research Facility
mi
from
Orlando, FL
A Study in Participants With Major Depressive Disorder Who Are Partial Responders to Selective Serotonin Reuptake Inhibitor
A Randomized Placebo-Controlled, Double-Blind Study of LY2216684 Flexible-Dose 12 to 18 mg Once Daily as Adjunctive Treatment for Patients With Major Depressive Disorder Who Are Partial Responders to Selective Serotonin Reuptake Inhibitor Treatment
Status: Enrolling
Updated: 3/26/2018
Clinical Research Facility
mi
from
Orlando, FL
Click here to add this to my saved trials
A Study in Participants With Major Depressive Disorder Who Are Partial Responders to Selective Serotonin Reuptake Inhibitor
A Randomized Placebo-Controlled, Double-Blind Study of LY2216684 Flexible-Dose 12 to 18 mg Once Daily as Adjunctive Treatment for Patients With Major Depressive Disorder Who Are Partial Responders to Selective Serotonin Reuptake Inhibitor Treatment
Status: Enrolling
Updated:  3/26/2018
Clinical Research Facility
mi
from
West Palm Beach, FL
A Study in Participants With Major Depressive Disorder Who Are Partial Responders to Selective Serotonin Reuptake Inhibitor
A Randomized Placebo-Controlled, Double-Blind Study of LY2216684 Flexible-Dose 12 to 18 mg Once Daily as Adjunctive Treatment for Patients With Major Depressive Disorder Who Are Partial Responders to Selective Serotonin Reuptake Inhibitor Treatment
Status: Enrolling
Updated: 3/26/2018
Clinical Research Facility
mi
from
West Palm Beach, FL
Click here to add this to my saved trials
A Study in Participants With Major Depressive Disorder Who Are Partial Responders to Selective Serotonin Reuptake Inhibitor
A Randomized Placebo-Controlled, Double-Blind Study of LY2216684 Flexible-Dose 12 to 18 mg Once Daily as Adjunctive Treatment for Patients With Major Depressive Disorder Who Are Partial Responders to Selective Serotonin Reuptake Inhibitor Treatment
Status: Enrolling
Updated:  3/26/2018
Clinical Research Facility
mi
from
Shreveport, LA
A Study in Participants With Major Depressive Disorder Who Are Partial Responders to Selective Serotonin Reuptake Inhibitor
A Randomized Placebo-Controlled, Double-Blind Study of LY2216684 Flexible-Dose 12 to 18 mg Once Daily as Adjunctive Treatment for Patients With Major Depressive Disorder Who Are Partial Responders to Selective Serotonin Reuptake Inhibitor Treatment
Status: Enrolling
Updated: 3/26/2018
Clinical Research Facility
mi
from
Shreveport, LA
Click here to add this to my saved trials
A Study in Participants With Major Depressive Disorder Who Are Partial Responders to Selective Serotonin Reuptake Inhibitor
A Randomized Placebo-Controlled, Double-Blind Study of LY2216684 Flexible-Dose 12 to 18 mg Once Daily as Adjunctive Treatment for Patients With Major Depressive Disorder Who Are Partial Responders to Selective Serotonin Reuptake Inhibitor Treatment
Status: Enrolling
Updated:  3/26/2018
Clinical Research Facility
mi
from
Lincoln, NE
A Study in Participants With Major Depressive Disorder Who Are Partial Responders to Selective Serotonin Reuptake Inhibitor
A Randomized Placebo-Controlled, Double-Blind Study of LY2216684 Flexible-Dose 12 to 18 mg Once Daily as Adjunctive Treatment for Patients With Major Depressive Disorder Who Are Partial Responders to Selective Serotonin Reuptake Inhibitor Treatment
Status: Enrolling
Updated: 3/26/2018
Clinical Research Facility
mi
from
Lincoln, NE
Click here to add this to my saved trials
A Study in Participants With Major Depressive Disorder Who Are Partial Responders to Selective Serotonin Reuptake Inhibitor
A Randomized Placebo-Controlled, Double-Blind Study of LY2216684 Flexible-Dose 12 to 18 mg Once Daily as Adjunctive Treatment for Patients With Major Depressive Disorder Who Are Partial Responders to Selective Serotonin Reuptake Inhibitor Treatment
Status: Enrolling
Updated:  3/26/2018
Clinical Research Facility
mi
from
Marlton, NJ
A Study in Participants With Major Depressive Disorder Who Are Partial Responders to Selective Serotonin Reuptake Inhibitor
A Randomized Placebo-Controlled, Double-Blind Study of LY2216684 Flexible-Dose 12 to 18 mg Once Daily as Adjunctive Treatment for Patients With Major Depressive Disorder Who Are Partial Responders to Selective Serotonin Reuptake Inhibitor Treatment
Status: Enrolling
Updated: 3/26/2018
Clinical Research Facility
mi
from
Marlton, NJ
Click here to add this to my saved trials
A Study in Participants With Major Depressive Disorder Who Are Partial Responders to Selective Serotonin Reuptake Inhibitor
A Randomized Placebo-Controlled, Double-Blind Study of LY2216684 Flexible-Dose 12 to 18 mg Once Daily as Adjunctive Treatment for Patients With Major Depressive Disorder Who Are Partial Responders to Selective Serotonin Reuptake Inhibitor Treatment
Status: Enrolling
Updated:  3/26/2018
Clinical Research Facility
mi
from
New York, NY
A Study in Participants With Major Depressive Disorder Who Are Partial Responders to Selective Serotonin Reuptake Inhibitor
A Randomized Placebo-Controlled, Double-Blind Study of LY2216684 Flexible-Dose 12 to 18 mg Once Daily as Adjunctive Treatment for Patients With Major Depressive Disorder Who Are Partial Responders to Selective Serotonin Reuptake Inhibitor Treatment
Status: Enrolling
Updated: 3/26/2018
Clinical Research Facility
mi
from
New York, NY
Click here to add this to my saved trials
A Study in Participants With Major Depressive Disorder Who Are Partial Responders to Selective Serotonin Reuptake Inhibitor
A Randomized Placebo-Controlled, Double-Blind Study of LY2216684 Flexible-Dose 12 to 18 mg Once Daily as Adjunctive Treatment for Patients With Major Depressive Disorder Who Are Partial Responders to Selective Serotonin Reuptake Inhibitor Treatment
Status: Enrolling
Updated:  3/26/2018
Clinical Research Facility
mi
from
Staten Island, NY
A Study in Participants With Major Depressive Disorder Who Are Partial Responders to Selective Serotonin Reuptake Inhibitor
A Randomized Placebo-Controlled, Double-Blind Study of LY2216684 Flexible-Dose 12 to 18 mg Once Daily as Adjunctive Treatment for Patients With Major Depressive Disorder Who Are Partial Responders to Selective Serotonin Reuptake Inhibitor Treatment
Status: Enrolling
Updated: 3/26/2018
Clinical Research Facility
mi
from
Staten Island, NY
Click here to add this to my saved trials
A Study in Participants With Major Depressive Disorder Who Are Partial Responders to Selective Serotonin Reuptake Inhibitor
A Randomized Placebo-Controlled, Double-Blind Study of LY2216684 Flexible-Dose 12 to 18 mg Once Daily as Adjunctive Treatment for Patients With Major Depressive Disorder Who Are Partial Responders to Selective Serotonin Reuptake Inhibitor Treatment
Status: Enrolling
Updated:  3/26/2018
Clinical Research Facility
mi
from
Cincinnati, OH
A Study in Participants With Major Depressive Disorder Who Are Partial Responders to Selective Serotonin Reuptake Inhibitor
A Randomized Placebo-Controlled, Double-Blind Study of LY2216684 Flexible-Dose 12 to 18 mg Once Daily as Adjunctive Treatment for Patients With Major Depressive Disorder Who Are Partial Responders to Selective Serotonin Reuptake Inhibitor Treatment
Status: Enrolling
Updated: 3/26/2018
Clinical Research Facility
mi
from
Cincinnati, OH
Click here to add this to my saved trials
A Study in Participants With Major Depressive Disorder Who Are Partial Responders to Selective Serotonin Reuptake Inhibitor
A Randomized Placebo-Controlled, Double-Blind Study of LY2216684 Flexible-Dose 12 to 18 mg Once Daily as Adjunctive Treatment for Patients With Major Depressive Disorder Who Are Partial Responders to Selective Serotonin Reuptake Inhibitor Treatment
Status: Enrolling
Updated:  3/26/2018
Clinical Research Facility
mi
from
Media, PA
A Study in Participants With Major Depressive Disorder Who Are Partial Responders to Selective Serotonin Reuptake Inhibitor
A Randomized Placebo-Controlled, Double-Blind Study of LY2216684 Flexible-Dose 12 to 18 mg Once Daily as Adjunctive Treatment for Patients With Major Depressive Disorder Who Are Partial Responders to Selective Serotonin Reuptake Inhibitor Treatment
Status: Enrolling
Updated: 3/26/2018
Clinical Research Facility
mi
from
Media, PA
Click here to add this to my saved trials
A Study in Participants With Major Depressive Disorder Who Are Partial Responders to Selective Serotonin Reuptake Inhibitor
A Randomized Placebo-Controlled, Double-Blind Study of LY2216684 Flexible-Dose 12 to 18 mg Once Daily as Adjunctive Treatment for Patients With Major Depressive Disorder Who Are Partial Responders to Selective Serotonin Reuptake Inhibitor Treatment
Status: Enrolling
Updated:  3/26/2018
Clinical Research Facility
mi
from
Herndon, VA
A Study in Participants With Major Depressive Disorder Who Are Partial Responders to Selective Serotonin Reuptake Inhibitor
A Randomized Placebo-Controlled, Double-Blind Study of LY2216684 Flexible-Dose 12 to 18 mg Once Daily as Adjunctive Treatment for Patients With Major Depressive Disorder Who Are Partial Responders to Selective Serotonin Reuptake Inhibitor Treatment
Status: Enrolling
Updated: 3/26/2018
Clinical Research Facility
mi
from
Herndon, VA
Click here to add this to my saved trials
A Study in Participants With Major Depressive Disorder Who Are Partial Responders to Selective Serotonin Reuptake Inhibitor
A Randomized Placebo-Controlled, Double-Blind Study of LY2216684 Flexible-Dose 12 to 18 mg Once Daily as Adjunctive Treatment for Patients With Major Depressive Disorder Who Are Partial Responders to Selective Serotonin Reuptake Inhibitor Treatment
Status: Enrolling
Updated:  3/26/2018
Clinical Research Facility
mi
from
Richmond, VA
A Study in Participants With Major Depressive Disorder Who Are Partial Responders to Selective Serotonin Reuptake Inhibitor
A Randomized Placebo-Controlled, Double-Blind Study of LY2216684 Flexible-Dose 12 to 18 mg Once Daily as Adjunctive Treatment for Patients With Major Depressive Disorder Who Are Partial Responders to Selective Serotonin Reuptake Inhibitor Treatment
Status: Enrolling
Updated: 3/26/2018
Clinical Research Facility
mi
from
Richmond, VA
Click here to add this to my saved trials
A Study in Participants With Major Depressive Disorder Who Are Partial Responders to Selective Serotonin Reuptake Inhibitor
A Randomized Placebo-Controlled, Double-Blind Study of LY2216684 Flexible-Dose 12 to 18 mg Once Daily as Adjunctive Treatment for Patients With Major Depressive Disorder Who Are Partial Responders to Selective Serotonin Reuptake Inhibitor Treatment
Status: Enrolling
Updated:  3/26/2018
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
mi
from
Everton Park,
A Study in Participants With Major Depressive Disorder Who Are Partial Responders to Selective Serotonin Reuptake Inhibitor
A Randomized Placebo-Controlled, Double-Blind Study of LY2216684 Flexible-Dose 12 to 18 mg Once Daily as Adjunctive Treatment for Patients With Major Depressive Disorder Who Are Partial Responders to Selective Serotonin Reuptake Inhibitor Treatment
Status: Enrolling
Updated: 3/26/2018
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
mi
from
Everton Park,
Click here to add this to my saved trials
fMRI-neuronavigated rTMS for the Treatment of Major Depression Associated With TBI
fMRI-neuronavigated Repetitive Transcranial Magnetic Stimulation for the Treatment of Major Depression Associated With Traumatic Brain Injury
Status: Enrolling
Updated:  3/26/2018
Washington University School of Medicine
mi
from
Saint Louis, MO
fMRI-neuronavigated rTMS for the Treatment of Major Depression Associated With TBI
fMRI-neuronavigated Repetitive Transcranial Magnetic Stimulation for the Treatment of Major Depression Associated With Traumatic Brain Injury
Status: Enrolling
Updated: 3/26/2018
Washington University School of Medicine
mi
from
Saint Louis, MO
Click here to add this to my saved trials
A Study for Participants With Major Depression
A Study of the Effects of LY2216684, a Selective Norepinephrine Reuptake Inhibitor (NERI), in the Treatment of Major Depression
Status: Enrolling
Updated:  3/26/2018
Clinical Research Facility
mi
from
Orlando, FL
A Study for Participants With Major Depression
A Study of the Effects of LY2216684, a Selective Norepinephrine Reuptake Inhibitor (NERI), in the Treatment of Major Depression
Status: Enrolling
Updated: 3/26/2018
Clinical Research Facility
mi
from
Orlando, FL
Click here to add this to my saved trials
A Study for Participants With Major Depression
A Study of the Effects of LY2216684, a Selective Norepinephrine Reuptake Inhibitor (NERI), in the Treatment of Major Depression
Status: Enrolling
Updated:  3/26/2018
Clinical Research Facility
mi
from
Prairie Village, KA
A Study for Participants With Major Depression
A Study of the Effects of LY2216684, a Selective Norepinephrine Reuptake Inhibitor (NERI), in the Treatment of Major Depression
Status: Enrolling
Updated: 3/26/2018
Clinical Research Facility
mi
from
Prairie Village, KA
Click here to add this to my saved trials
A Study for Participants With Major Depression
A Study of the Effects of LY2216684, a Selective Norepinephrine Reuptake Inhibitor (NERI), in the Treatment of Major Depression
Status: Enrolling
Updated:  3/26/2018
Clinical Research Facility
mi
from
Allentown, PA
A Study for Participants With Major Depression
A Study of the Effects of LY2216684, a Selective Norepinephrine Reuptake Inhibitor (NERI), in the Treatment of Major Depression
Status: Enrolling
Updated: 3/26/2018
Clinical Research Facility
mi
from
Allentown, PA
Click here to add this to my saved trials
A Study for Participants With Major Depression
A Study of the Effects of LY2216684, a Selective Norepinephrine Reuptake Inhibitor (NERI), in the Treatment of Major Depression
Status: Enrolling
Updated:  3/26/2018
Clinical Research Facility
mi
from
Media, PA
A Study for Participants With Major Depression
A Study of the Effects of LY2216684, a Selective Norepinephrine Reuptake Inhibitor (NERI), in the Treatment of Major Depression
Status: Enrolling
Updated: 3/26/2018
Clinical Research Facility
mi
from
Media, PA
Click here to add this to my saved trials
A Study for Participants With Major Depression
A Study of the Effects of LY2216684, a Selective Norepinephrine Reuptake Inhibitor (NERI), in the Treatment of Major Depression
Status: Enrolling
Updated:  3/26/2018
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
mi
from
Bucharest,
A Study for Participants With Major Depression
A Study of the Effects of LY2216684, a Selective Norepinephrine Reuptake Inhibitor (NERI), in the Treatment of Major Depression
Status: Enrolling
Updated: 3/26/2018
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
mi
from
Bucharest,
Click here to add this to my saved trials
Administration of Subanesthetic Dose of Ketamine and Electroconvulsive Treatment for Treatment Resistant Depression
Administration of Subanesthetic Dose of Ketamine and Electroconvulsive Treatment on Alternate Week Days in Patients With Treatment Resistant Depression: A Double Blind Placebo Controlled Trial
Status: Enrolling
Updated:  3/27/2018
Cleveland Clinic Foundation Center for Behavioral Health
mi
from
Cleveland, OH
Administration of Subanesthetic Dose of Ketamine and Electroconvulsive Treatment for Treatment Resistant Depression
Administration of Subanesthetic Dose of Ketamine and Electroconvulsive Treatment on Alternate Week Days in Patients With Treatment Resistant Depression: A Double Blind Placebo Controlled Trial
Status: Enrolling
Updated: 3/27/2018
Cleveland Clinic Foundation Center for Behavioral Health
mi
from
Cleveland, OH
Click here to add this to my saved trials
Dichotic Listening as a Predictor of Medication Response in Depression
Dichotic Listening as a Predictor of Medication Response in Depression
Status: Enrolling
Updated:  3/29/2018
New York State Psychiatric Institute
mi
from
New York, NY
Dichotic Listening as a Predictor of Medication Response in Depression
Dichotic Listening as a Predictor of Medication Response in Depression
Status: Enrolling
Updated: 3/29/2018
New York State Psychiatric Institute
mi
from
New York, NY
Click here to add this to my saved trials
Safety and Efficacy of Cariprazine as an Adjunctive to Antidepressant Therapy in Major Depressive Disorder
A Double-Blind, Placebo-Controlled Study of Cariprazine (RGH-188) as Adjunctive Therapy in Major Depressive Disorder
Status: Enrolling
Updated:  3/29/2018
Forest Investigative Site #021
mi
from
Garden Grove, CA
Safety and Efficacy of Cariprazine as an Adjunctive to Antidepressant Therapy in Major Depressive Disorder
A Double-Blind, Placebo-Controlled Study of Cariprazine (RGH-188) as Adjunctive Therapy in Major Depressive Disorder
Status: Enrolling
Updated: 3/29/2018
Forest Investigative Site #021
mi
from
Garden Grove, CA
Click here to add this to my saved trials
Safety and Efficacy of Cariprazine as an Adjunctive to Antidepressant Therapy in Major Depressive Disorder
A Double-Blind, Placebo-Controlled Study of Cariprazine (RGH-188) as Adjunctive Therapy in Major Depressive Disorder
Status: Enrolling
Updated:  3/29/2018
Forest Investigative Site 019
mi
from
National City, CA
Safety and Efficacy of Cariprazine as an Adjunctive to Antidepressant Therapy in Major Depressive Disorder
A Double-Blind, Placebo-Controlled Study of Cariprazine (RGH-188) as Adjunctive Therapy in Major Depressive Disorder
Status: Enrolling
Updated: 3/29/2018
Forest Investigative Site 019
mi
from
National City, CA
Click here to add this to my saved trials
Safety and Efficacy of Cariprazine as an Adjunctive to Antidepressant Therapy in Major Depressive Disorder
A Double-Blind, Placebo-Controlled Study of Cariprazine (RGH-188) as Adjunctive Therapy in Major Depressive Disorder
Status: Enrolling
Updated:  3/29/2018
Forest Investigative Site
mi
from
Oceanside, CA
Safety and Efficacy of Cariprazine as an Adjunctive to Antidepressant Therapy in Major Depressive Disorder
A Double-Blind, Placebo-Controlled Study of Cariprazine (RGH-188) as Adjunctive Therapy in Major Depressive Disorder
Status: Enrolling
Updated: 3/29/2018
Forest Investigative Site
mi
from
Oceanside, CA
Click here to add this to my saved trials
Safety and Efficacy of Cariprazine as an Adjunctive to Antidepressant Therapy in Major Depressive Disorder
A Double-Blind, Placebo-Controlled Study of Cariprazine (RGH-188) as Adjunctive Therapy in Major Depressive Disorder
Status: Enrolling
Updated:  3/29/2018
Forest Investigative Site 009
mi
from
Orange, CA
Safety and Efficacy of Cariprazine as an Adjunctive to Antidepressant Therapy in Major Depressive Disorder
A Double-Blind, Placebo-Controlled Study of Cariprazine (RGH-188) as Adjunctive Therapy in Major Depressive Disorder
Status: Enrolling
Updated: 3/29/2018
Forest Investigative Site 009
mi
from
Orange, CA
Click here to add this to my saved trials
Safety and Efficacy of Cariprazine as an Adjunctive to Antidepressant Therapy in Major Depressive Disorder
A Double-Blind, Placebo-Controlled Study of Cariprazine (RGH-188) as Adjunctive Therapy in Major Depressive Disorder
Status: Enrolling
Updated:  3/29/2018
Forest Investigative Site 009
mi
from
Orange, CA
Safety and Efficacy of Cariprazine as an Adjunctive to Antidepressant Therapy in Major Depressive Disorder
A Double-Blind, Placebo-Controlled Study of Cariprazine (RGH-188) as Adjunctive Therapy in Major Depressive Disorder
Status: Enrolling
Updated: 3/29/2018
Forest Investigative Site 009
mi
from
Orange, CA
Click here to add this to my saved trials
Safety and Efficacy of Cariprazine as an Adjunctive to Antidepressant Therapy in Major Depressive Disorder
A Double-Blind, Placebo-Controlled Study of Cariprazine (RGH-188) as Adjunctive Therapy in Major Depressive Disorder
Status: Enrolling
Updated:  3/29/2018
Forest Investigative Site 009
mi
from
Orange, CA
Safety and Efficacy of Cariprazine as an Adjunctive to Antidepressant Therapy in Major Depressive Disorder
A Double-Blind, Placebo-Controlled Study of Cariprazine (RGH-188) as Adjunctive Therapy in Major Depressive Disorder
Status: Enrolling
Updated: 3/29/2018
Forest Investigative Site 009
mi
from
Orange, CA
Click here to add this to my saved trials
Safety and Efficacy of Cariprazine as an Adjunctive to Antidepressant Therapy in Major Depressive Disorder
A Double-Blind, Placebo-Controlled Study of Cariprazine (RGH-188) as Adjunctive Therapy in Major Depressive Disorder
Status: Enrolling
Updated:  3/29/2018
Forest Investigative Site 008
mi
from
Redlands, CA
Safety and Efficacy of Cariprazine as an Adjunctive to Antidepressant Therapy in Major Depressive Disorder
A Double-Blind, Placebo-Controlled Study of Cariprazine (RGH-188) as Adjunctive Therapy in Major Depressive Disorder
Status: Enrolling
Updated: 3/29/2018
Forest Investigative Site 008
mi
from
Redlands, CA
Click here to add this to my saved trials
Safety and Efficacy of Cariprazine as an Adjunctive to Antidepressant Therapy in Major Depressive Disorder
A Double-Blind, Placebo-Controlled Study of Cariprazine (RGH-188) as Adjunctive Therapy in Major Depressive Disorder
Status: Enrolling
Updated:  3/29/2018
Forest Investigative Site #003
mi
from
Sherman Oaks, CA
Safety and Efficacy of Cariprazine as an Adjunctive to Antidepressant Therapy in Major Depressive Disorder
A Double-Blind, Placebo-Controlled Study of Cariprazine (RGH-188) as Adjunctive Therapy in Major Depressive Disorder
Status: Enrolling
Updated: 3/29/2018
Forest Investigative Site #003
mi
from
Sherman Oaks, CA
Click here to add this to my saved trials
Safety and Efficacy of Cariprazine as an Adjunctive to Antidepressant Therapy in Major Depressive Disorder
A Double-Blind, Placebo-Controlled Study of Cariprazine (RGH-188) as Adjunctive Therapy in Major Depressive Disorder
Status: Enrolling
Updated:  3/29/2018
Forest Investigative Site 1543
mi
from
Jacksonville, FL
Safety and Efficacy of Cariprazine as an Adjunctive to Antidepressant Therapy in Major Depressive Disorder
A Double-Blind, Placebo-Controlled Study of Cariprazine (RGH-188) as Adjunctive Therapy in Major Depressive Disorder
Status: Enrolling
Updated: 3/29/2018
Forest Investigative Site 1543
mi
from
Jacksonville, FL
Click here to add this to my saved trials
Safety and Efficacy of Cariprazine as an Adjunctive to Antidepressant Therapy in Major Depressive Disorder
A Double-Blind, Placebo-Controlled Study of Cariprazine (RGH-188) as Adjunctive Therapy in Major Depressive Disorder
Status: Enrolling
Updated:  3/29/2018
Forest Investigative Site
mi
from
Kissimmee, FL
Safety and Efficacy of Cariprazine as an Adjunctive to Antidepressant Therapy in Major Depressive Disorder
A Double-Blind, Placebo-Controlled Study of Cariprazine (RGH-188) as Adjunctive Therapy in Major Depressive Disorder
Status: Enrolling
Updated: 3/29/2018
Forest Investigative Site
mi
from
Kissimmee, FL
Click here to add this to my saved trials
Safety and Efficacy of Cariprazine as an Adjunctive to Antidepressant Therapy in Major Depressive Disorder
A Double-Blind, Placebo-Controlled Study of Cariprazine (RGH-188) as Adjunctive Therapy in Major Depressive Disorder
Status: Enrolling
Updated:  3/29/2018
Forest Investigative site 067
mi
from
Miami, FL
Safety and Efficacy of Cariprazine as an Adjunctive to Antidepressant Therapy in Major Depressive Disorder
A Double-Blind, Placebo-Controlled Study of Cariprazine (RGH-188) as Adjunctive Therapy in Major Depressive Disorder
Status: Enrolling
Updated: 3/29/2018
Forest Investigative site 067
mi
from
Miami, FL
Click here to add this to my saved trials
Safety and Efficacy of Cariprazine as an Adjunctive to Antidepressant Therapy in Major Depressive Disorder
A Double-Blind, Placebo-Controlled Study of Cariprazine (RGH-188) as Adjunctive Therapy in Major Depressive Disorder
Status: Enrolling
Updated:  3/29/2018
Forest Investigative Site 061
mi
from
Orlando, FL
Safety and Efficacy of Cariprazine as an Adjunctive to Antidepressant Therapy in Major Depressive Disorder
A Double-Blind, Placebo-Controlled Study of Cariprazine (RGH-188) as Adjunctive Therapy in Major Depressive Disorder
Status: Enrolling
Updated: 3/29/2018
Forest Investigative Site 061
mi
from
Orlando, FL
Click here to add this to my saved trials
Safety and Efficacy of Cariprazine as an Adjunctive to Antidepressant Therapy in Major Depressive Disorder
A Double-Blind, Placebo-Controlled Study of Cariprazine (RGH-188) as Adjunctive Therapy in Major Depressive Disorder
Status: Enrolling
Updated:  3/29/2018
Forest Investigative Site
mi
from
Atlanta, GA
Safety and Efficacy of Cariprazine as an Adjunctive to Antidepressant Therapy in Major Depressive Disorder
A Double-Blind, Placebo-Controlled Study of Cariprazine (RGH-188) as Adjunctive Therapy in Major Depressive Disorder
Status: Enrolling
Updated: 3/29/2018
Forest Investigative Site
mi
from
Atlanta, GA
Click here to add this to my saved trials
Safety and Efficacy of Cariprazine as an Adjunctive to Antidepressant Therapy in Major Depressive Disorder
A Double-Blind, Placebo-Controlled Study of Cariprazine (RGH-188) as Adjunctive Therapy in Major Depressive Disorder
Status: Enrolling
Updated:  3/29/2018
Forest Investigative Site 071
mi
from
Prairie Village, KA
Safety and Efficacy of Cariprazine as an Adjunctive to Antidepressant Therapy in Major Depressive Disorder
A Double-Blind, Placebo-Controlled Study of Cariprazine (RGH-188) as Adjunctive Therapy in Major Depressive Disorder
Status: Enrolling
Updated: 3/29/2018
Forest Investigative Site 071
mi
from
Prairie Village, KA
Click here to add this to my saved trials
Safety and Efficacy of Cariprazine as an Adjunctive to Antidepressant Therapy in Major Depressive Disorder
A Double-Blind, Placebo-Controlled Study of Cariprazine (RGH-188) as Adjunctive Therapy in Major Depressive Disorder
Status: Enrolling
Updated:  3/29/2018
Forest Investigative Site 001
mi
from
Flowood, MS
Safety and Efficacy of Cariprazine as an Adjunctive to Antidepressant Therapy in Major Depressive Disorder
A Double-Blind, Placebo-Controlled Study of Cariprazine (RGH-188) as Adjunctive Therapy in Major Depressive Disorder
Status: Enrolling
Updated: 3/29/2018
Forest Investigative Site 001
mi
from
Flowood, MS
Click here to add this to my saved trials
Safety and Efficacy of Cariprazine as an Adjunctive to Antidepressant Therapy in Major Depressive Disorder
A Double-Blind, Placebo-Controlled Study of Cariprazine (RGH-188) as Adjunctive Therapy in Major Depressive Disorder
Status: Enrolling
Updated:  3/29/2018
Forest Investigative Site 022
mi
from
Creve Coeur, MO
Safety and Efficacy of Cariprazine as an Adjunctive to Antidepressant Therapy in Major Depressive Disorder
A Double-Blind, Placebo-Controlled Study of Cariprazine (RGH-188) as Adjunctive Therapy in Major Depressive Disorder
Status: Enrolling
Updated: 3/29/2018
Forest Investigative Site 022
mi
from
Creve Coeur, MO
Click here to add this to my saved trials
Safety and Efficacy of Cariprazine as an Adjunctive to Antidepressant Therapy in Major Depressive Disorder
A Double-Blind, Placebo-Controlled Study of Cariprazine (RGH-188) as Adjunctive Therapy in Major Depressive Disorder
Status: Enrolling
Updated:  3/29/2018
Forest Investigative Site 023
mi
from
Cherry Hill, NJ
Safety and Efficacy of Cariprazine as an Adjunctive to Antidepressant Therapy in Major Depressive Disorder
A Double-Blind, Placebo-Controlled Study of Cariprazine (RGH-188) as Adjunctive Therapy in Major Depressive Disorder
Status: Enrolling
Updated: 3/29/2018
Forest Investigative Site 023
mi
from
Cherry Hill, NJ
Click here to add this to my saved trials
Safety and Efficacy of Cariprazine as an Adjunctive to Antidepressant Therapy in Major Depressive Disorder
A Double-Blind, Placebo-Controlled Study of Cariprazine (RGH-188) as Adjunctive Therapy in Major Depressive Disorder
Status: Enrolling
Updated:  3/29/2018
Forest Investigative Site
mi
from
Albuquerque, NM
Safety and Efficacy of Cariprazine as an Adjunctive to Antidepressant Therapy in Major Depressive Disorder
A Double-Blind, Placebo-Controlled Study of Cariprazine (RGH-188) as Adjunctive Therapy in Major Depressive Disorder
Status: Enrolling
Updated: 3/29/2018
Forest Investigative Site
mi
from
Albuquerque, NM
Click here to add this to my saved trials